leadf
logo-loader
viewSareum Holdings PLC

Sareum Holdings plans to raise £718,500 via share placing

The group also confirmed it “continues to engage with interested parties regarding the further development and potential commercialisation” of TYK2/JAK1 drugs SDC-1801 and SDC-1802

Sareum Holdings PLC -

Sareum Holdings PLC (LON:SAR) has said it is raising £718,500 before expenses via a placing of shares at 0.6p each with the new funds used to explore the potential benefit of its TYK2/JAK1 inhibitors against coronavirus (COVID-19).

A separate fundraiser overseen by PrimaryBid will offer private investors new shares in the company on the same terms.

As at March 31, 2020, Sareum had cash of £980,000. It expects to receive a research and development tax credit next January of £150,000.

Outside of the potential COVID-19 indication, the firm is focused on the pre-clinical development of its small-molecule TYK2/JAK1 inhibitors for cancer and autoimmune diseases. Preparatory work is being made to advance candidates towards human trials.

In an announcement, the group also confirmed it “continues to engage with interested parties regarding the further development and potential commercialisation” of TYK2/JAK1 drugs SDC-1801 and SDC-1802.

“We are targeting the completion of at least one preclinical study in the fourth quarter and are developing our plans for the initial clinical trials with both compounds,” said chief executive Tim Mitchell.

Quick facts: Sareum Holdings PLC

Price: 2.2 GBX

AIM:SAR
Market: AIM
Market Cap: £71.89 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Sareum Holdings PLC named herein, including the promotion by the Company of Sareum Holdings PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Sareum Holdings focused on striking a deal for its immunotherapies

Sareum Holdings PLC's (LON:SAR) Tim Mitchell tells Proactive London's Andrew Scott they're advancing initial discussions with potential licensees for its pre-clinical tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitor immunotherapies for autoimmune diseases and cancer. He says they're...

on 12/8/20

2 min read